Background: The lipid-lowering effect of fenofi brate is accompanied by a rise in plasma homocysteine (HCY), a potential risk factor for venous thromboembolism (VTE). This study investigated the relationship between HCY and the risk of VTE in patients treated with fenofi brate. Methods: The relationship between HCY and deep-vein thrombosis or pulmonary embolism was investigated in 9522 participants of the 5-year Fenofi brate Intervention and Event Lowering in Diabetes (FIELD) trial. All subjects received fenofi brate during a 6-week active run-in phase before randomization. A Cox proportional-hazards model was used to assess the effect of HCY on risk of venous thromboembolic events. Results: During active-drug run-in, HCY rose on average by 6.5 μ mol/L, accompanied by a substantial rise in plasma creatinine ( + 12 % ). Fenofi brate-induced changes in HCY and creatinine were fully reversible in the placebo group but persisted in the treatment group until reversing at the end of therapy. During follow-up, 1.8 % had at least one episode of deep-vein thrombosis or pulmonary embolism: 103 on fenofi brate and 68 on placebo (log-rank p = 0.006). In multivariate analysis, every 5 μ mol/L higher baseline HCY was associated with 19 % higher risk of VTE. Fenofi brate treatment was associated with 52 % higher risk, but the change in HCY with fenofi brate was not signifi cantly associated with VTE after adjustment for baseline HCY.
Introduction
Lipid-lowering drug therapy is one of the mainstays of primary and secondary prevention of cardiovascular disease (1 -3) . Although statins are the most commonly prescribed lipid-lowering agents, they are not the most effective agents for lowering triglycerides (3 -5) . Fibrates, such as fenofi brate, are known to lower triglycerides and, to a lesser extent, cholesterol (6) . Fibrate therapy is of particular relevance in diabetes, where triglycerides are often elevated (7, 8) . In the large-scale Fenofi brate Intervention and Event Lowering in Diabetes (FIELD) trial, long-term fenofi brate treatment reduced triglycerides by 27 % , total cholesterol by 11 % , and low-density lipoprotein (LDL) cholesterol by 11 % in patients with type 2 diabetes (9) . Although fenofi brate did not signifi cantly reduce the risk of the primary outcome of coronary events, it did signifi cantly reduce cardiovascular events. Furthermore, fenofi brate caused a marked reduction in microvascular events including retinopathy, nephropathy and neuropathy. The benefi cial effects of fenofi brate were evident, despite an associated increase in the serum level of homocysteine (HCY), which is an established risk factor for cardiovascular disease (CVD) (10) . The HCY-increasing effect of fenofi brate also raises the question whether fenofi brate treatment increases the likelihood of venous thromboembolism (VTE) events, because there is some evidence that HCY increases venous thromboembolism (11 -13) .
Case-control studies from the 1990s reported a high prevalence of mild to moderate hyperhomocysteinemia in VTE patients (11, 14 -17) . However, the impact of these studies is limited by their retrospective nature and the small number of cases. Prospective studies have been rare, with a total of 476 cases and 1517 controls in three studies (12) . Although they generally confi rmed hyperhomocysteinemia as a risk factor, the associations were statistically weak, creating uncertainty about the causality of hyperhomocysteinemia for VTE. The common C677T polymorphism of the methylenetetrahydrofolate reductase ( MTHFR ) gene also contributes to elevated HCY concentrations, especially when present in the homozygous form. Studies investigating the potential relationship between this polymorphism and VTE have been inconsistent. A meta-analysis including 31 studies showed a weak association between the MTHFR C677T gene polymorphism and an increased risk of VTE (18) . The authors speculated that the relationship between hyperhomocysteinemia and VTE is unlikely to be mediated by this gene defect to a substantial degree.
The limited number of prospective studies and their inconclusive outcomes highlight the need for additional prospective data investigating the relationship between serum HCY and VTE.
Our study investigates the relation between HCY and venous thrombolism in the FIELD trial, in which patients with type 2 diabetes mellitus were treated with placebo or fenofi brate for an average of 5 years. Since fenofi brate is known to increase HCY (10) , we also investigated whether fenofi brate-induced changes in HCY modify the risk of future thrombotic events.
Materials and methods

Study design
The FIELD trial was a multinational, double-blind, placebo-controlled trial in 63 centers in Australia, New Zealand, and Finland. The study population consisted of 9795 participants aged 50 -75 years who had type 2 diabetes mellitus diagnosed according to WHO criteria and who were not taking lipid-modifying therapy at study entry. A detailed description of the design of the study has been published (19) . Between February 1998 and November 2000, patients were randomly allocated to once-daily micronized fenofi brate (Laboratoires Fournier, Dijon, France), 200 mg, or placebo. Patients were recruited from hospital clinics and community sources. Exclusion criteria included renal impairment (blood creatinine > 130 μ mol/L), known chronic liver disease or symptomatic gallbladder disease, and a cardiovascular event within the 3 months before recruitment.
Before randomization all participants entered a standardized run-in phase consisting of a 4-week diet-only period, a 6-week single-blind placebo period, and then a 6-week single-blind active run-in period on the study treatment ( Figure 1 ). This allows determination of the correlation between any long-term clinical effects of treatment and short-term alterations associated with the drug, including changes in circulating HCY levels. HCY results and complete medical records were available from 9522 participants at baseline and from 8182 at the end of the active run-in phase. Venous thrombotic events were assessed on clinical grounds, usually consisting of the hospital discharge summary. They were also notifi ed as serious adverse events.
All patients gave written informed consent. The study protocol was approved by Local and National Ethics Committees and was undertaken in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
Blood sampling and measurement of homocysteine
Plasma HCY was measured before the 6-week active-treatment run-in (at baseline) and at the end (at randomization). Fasting blood samples were collected into EDTA tubes. Immediately after collection, samples were separated and frozen on site. Frozen samples were transported to one of two central laboratories in Adelaide (Australia) and Helsinki (Finland) where they were aliquoted and stored at -80 ° C until analysis. In the Australian laboratory, plasma HCY was assayed by high-performance liquid chromatography (HPLC) after reduction and derivatization with a fl uorophore. In Finland a commercial immunoassay was used. These methods are known to produce comparable results and were confi rmed by the exchange of samples between the two laboratories. In both laboratories the assay performance was monitored over time by internal quality-control procedures and participation in local external quality-assurance programs.
Statistical analysis
The main outcome studied was the time from randomization to a deep-vein thrombosis or pulmonary embolism event. Circulating biomarkers were expressed as mean and standard deviation, or median with interquartile range if data were not normally distributed. Calculations of relative change were based on log-transformed data using the ratio of geometric means.
Cumulative hazard curves of events according to treatment group were plotted, and the log-rank test was used to ascertain the effect of fenofi brate treatment on the fi rst VTE event. A Cox proportional-hazards model was used to assess the effect of HCY on the risk of VTE events. Hazard ratios (HRs) and 95 % confi dence intervals (CI) are presented. The proportional-hazards assumption was assessed using the Harrell-Lee test (20) . Selection of predictor variables was performed using the backward elimination method. For the purposes of analysis, change in HCY was defi ned as the difference between baseline and end-of-run-in HCY levels for each subject in the fenofi braterandomized group, and zero change was attributed to all subjects in the placebo group (based on the lack of change in average levels in placebo-treated subjects at 1 year). Since previous studies have speculated about the existence of a HCY threshold level above which VTE risk starts to rise (11, 21, 22) , we investigated whether there was evidence for such a threshold in the FIELD cohort. The relationship between quintiles of HCY and risk was assessed in an intention-to-treat analysis using an adjusted Cox model. Fractional polynomials, a fl exible tool for modeling the relationship between the continuous variable, plasma HCY, and VTE, were fi tted (23) . We considered models of up to 2 degrees.
Analyses were performed using SAS version 9.2, and a two-tailed p < 0.05 was considered signifi cant.
Results
Baseline characteristics and effects of fenofi brate on circulating biomarkers
Participants in the placebo and fenofi brate groups were well matched for baseline characteristics, such as age, body mass index, smoking habits, blood pressure and duration of diabetes (Table 1 ) . Both groups had a similar history of cardiovascular events. The use of glucose-lowering and cardiovascular medication was as expected for a cohort of people with diabetes and did not differ between the two groups. Baseline HCY levels were similar in the placebo group (Table 2 ) and the fenofi brate group. Similarly, other biochemical serum or plasma markers including creatinine, fi brinogen and lipoprotein (Lp) (a) also showed comparable baseline levels.
While placebo treatment had no effect on any relevant biomarker over the short-to-medium term (1 year), fenofi brate induced signifi cant changes in HCY and creatinine. During the active run-in phase (before randomization; all participants were treated with fenofi brate for 6 weeks), plasma HCY rose on average by 6.5 μ mol/L in both groups. The increase in HCY was accompanied by a substantial rise in plasma creatinine by 10.0 μ mol/L ( + 12 % ). A Spearman ' s correlation analysis showed a signifi cant correlation between the change in HCY and the change in creatinine with a correlation coeffi cient of r = 0.38, p < 0.001.
Repeat measurements after 1 and 5 years of treatment showed that the fenofi brate-induced changes in HCY and creatinine were fully reversible in those randomized to placebo after active run-in, but persisted in the treatment group long-term. However, after randomization to long-term fenofi brate, HCY stabilized at somewhat lower levels when compared with the initial increase at the end of the 6-week run-in Normally distributed variables are shown as mean (SD), non-normally distributed as median (25th to 75th interquartile range).
phase. In contrast, creatinine levels remained elevated during the entire follow-up period .
Description of events
During the follow-up period, 171 patients (1.8 % of the entire cohort) had a least one deep-vein thrombosis or pulmonary embolism event (221 events). While most of these patients (76.6 % ) had only one event, 23.4 % sustained two or more. In the fenofi brate group 103 patients had an event, compared with 68 patients in the placebo group (Figure 2 ; log-rank p = 0.006). Overall, deep-vein thrombosis was more frequent than pulmonary embolism. One hundred and ten and 85 patients had at least one deep vein thrombosis and pulmonary embolism event, respectively. The HRs comparing the incidence of thrombosis events between fenofi brate-and placebo-treated participants remained relatively constant throughout the trial, with no statistical heterogeneity observed in hazard ratios across arbitrary time periods (0 -2 years, 2 -4 years, > 4 years).
Relationship between homocysteine and the risk of thrombosis events
Before exploring the relationship between HCY and thrombosis risk, potential confounders were identifi ed using univariate and multivariate analyses. These analyses identifi ed the following parameters as signifi cant predictors of thrombotic risk: age, BMI, ethnicity, history of hypertension, history of CVD, neuropathy and the albumin/creatinine ratio. Those remaining signifi cant in multivariate analysis were age, ethnicity, history of CVD and BMI. Adjusting for all these potential confounders revealed baseline HCY and the use of fenofi brate as signifi cant independent predictors of thrombosis risk (Table 3 ) . Each 5 μ mol/L higher plasma HCY at baseline was associated with 19 % higher risk. Fenofi brate treatment was associated with a 52 % higher risk of thrombosis. Fenofi brate appeared more likely to increase thrombotic risk in those with highest baseline HCY levels (interaction p = 0.04). The change in HCY with fenofi brate was not signifi cantly associated with thromboembolism after adjustment for baseline HCY level (Table 4 ) .
Is there a homocysteine threshold level above which venous thromboembolism risk increases ?
The HRs for VTE by quintile of plasma HCY level showed no evidence of a threshold effect. In models of the relationship using plasma HCY as a continuous variable, none of the 
Discussion
This study provides evidence that naturally occurring levels of plasma HCY are associated with risk of future VTE events. A 5 μ mol/L difference in plasma HCY was associated with a 19 % difference in the risk of thrombotic events. This observation is in keeping with previous case-control studies reporting a high prevalence of hyperhomocysteinemia in VTE patients (11, 14 -17) . Prospective studies are rare, and together comprise a total of only 476 VTE cases and 1517 controls (12) . Their results were variable (24, 25) . For example, Ridker et al. did not fi nd a higher risk of VTE in people with plasma HCY levels ≥ 17.25 μ mol/L compared to those with lower levels (24) . Similarly, Tsai et al. found a non-signifi cantly higher thromboembolism risk in the highest quintile of serum HCY (adjusted odds ratio 1.55; 95 % CI, 0.93 -2.58) (25) . In the present study baseline HCY was a signifi cant predictor of thrombotic events in the entire cohort but not in the placebo group suggesting that overall this relationship is not very strong. A meta-analysis, pooling the data from all available prospective studies showed a 27 % increase in thrombosis risk (odds ratio 1.27; 95 % CI, 1.01 -1.59) for every 5 μ mol/L higher circulating HCY (12) , which is comparable to our result. The mechanisms underlying the association between HCY and VTE risk are complex and insuffi ciently understood. HCY causes oxidative stress and endothelial damage. Furthermore, it activates platelets, promotes local thrombin formation and impairs fi brinolysis (26, 27) . The induction of endothelial tissue factor expression and the inhibition of plasminogen activation by tissue plasminogen activator appear to be of pivotal importance (26, 28, 29) . For example, HCY increases the expression of plasminogen activator inhibitor-1 and thrombin-activatable fi brinolysis inhibitor (26, 29) . Adverse effects on angiogenesis resulting in angiostasis have also been described. (26, 28) . It has been suggested that hyperhomocysteinemia potentiates the thrombotic risk in carriers of inherited thrombophilic factors, such as Factor V Leiden or the prothrombin G20210A mutation (30) . However, existing studies investigating such interactions are contradictory. When compared to normal individuals some studies found a 10-to 50-fold higher VTE risk in hyperhomocysteinemic carriers of a prothrombotic mutation, suggesting a synergistic effect. Other studies were not able to confi rm this observation. In fact, the co-existence of the C677T MTHFR homozygous genotype does not increase the thrombotic risk associated with Factor V Leiden or the prothrombin G20210A mutation. As yet, in the FIELD cohort there is no information available about the frequency and distribution of these hereditary prothrombotic conditions.
In our study plasma HCY promptly rose during fenofi brate treatment. The concomitant elevation of plasma creatinine suggests a possible alteration in renal metabolism. Previous studies have shown that HCY is consistently elevated in patients with renal impairment and glomerular fi ltration rate (GFR) < 60 mL/min (31 -33) . Although creatinine increased during fenofi brate therapy in FIELD, the albumin/creatinine ratio did not rise suggesting that the excretory renal function was not impaired. In addition, the correlation between the change in HCY and the change in creatinine was relatively weak (R = 0.38) suggesting that an altered renal HCY handling explains only a minor fraction of this effect. When a subset of patients was retested after discontinuation of fenofi brate at the end of the study, HCY levels returned to baseline whilst creatinine levels even fell slightly below baseline levels, implying signifi cant reno-protective effects (34) . Therefore, we speculate that the elevation of HCY, and possibly creatinine, is due to increased synthesis via PPAR alpha activation, as suggested by Luc et al. (35) .
Despite the benefi cial effects of fenofi brate on various homoeostatic indices (36) and infl ammatory markers (37) the present results suggest fenofi brate use as an independent risk factor for VTE (52 % risk increase). Although fenofi brate also induces a substantial rise in plasma HCY levels, the lack of an interaction between fenofi brate use and the extent of increase in HCY levels does not support this being the sole mechanism of the greater risk associated with its use. In a previous study Lacut et al. also observed an increased risk of VTE events in fenofi brate users which was independent of plasma HCY (OR 1.88; 95 % CI 1.29 -2.74) (38) . An altered lipid handling may at least partly be responsible for this observation. Fenofi brate, for example, induces the expression of uncoupling proteins (UCP), such as UCP 2 and 3, in liver and skeletal muscle (39) . Furthermore, it affects elongase and desaturase, which are important in fatty acid metabolism (40, 41) . This may lead to an altered lipidprofi le favoring the formation of clots (42) . In contrast to the present fi ndings, other studies, such as the recently published ACCORD Lipid trial, have reported fenofi brate to be safe and did not observe increased rates of VTE (43, 44) . In the context of a relatively weak interaction between baseline HCY and fenofi brate this raises the possibility that the increased risk associated with fenofi brate in FIELD may be a chance false-positive fi nding from among the several hundred types of safety outcomes collected in the FIELD study. Another possibility is that the result is confounded by the greater number of patients in the placebo group commencing statin use during the study. Statin therapy has been shown to have a modest protective effect against VTE events (45, 46) , but a multivariate model adjusting for differences in statin use confi rmed baseline HCY and fenofi brate as independent predictors of future VTE. The results may refl ect the variable interaction of several factors over the duration of the study. In the early phase, the interaction between baseline HCY and fenofi brate induced increase in HCY may have predominated, whilst in the later phase, when the fenofi brate induced increase in HCY had abated, the higher rate of statin use may have provided relative protection towards the placebo group. The baseline levels of other potential thrombophilic risk factors, such as fi brinogen and Lp(a), did not show signifi cant associations with future thrombotic events. This emphasizes the role of baseline HCY and fenofi brate treatment as independent risk factors for venous thromboembolism.
den Heijer et al. suggested that VTE risk starts to rise if natural HCY levels exceed a threshold of about 17 μ mol/L (11) . Despite higher on-study plasma HCY levels (approx. 4 μ mol/L) and signifi cantly more VTE events ( + 52 % ) in the fenofi brate group when compared to the placebo group, all our analyses failed to confi rm the existence of such a threshold. The FIELD cohort had relatively low average plasma HCY, and only a few participants had elevated plasma HCY levels. This may have prevented the detection of a HCY threshold above which VTE risk starts to rise.
In conclusion, data from the FIELD trial confi rm previous fi ndings that suggest that natural HCY levels are an independent risk factor for VTE events. Unlike the ACCORD Lipid study, in which all participants received statin therapy, the use of fenofi brate in FIELD increased the risk for thrombotic events, especially in patients with high pre-treatment plasma HCY. Although fenofi brate increased HCY levels in FIELD, there was no interaction between the extent of HCY elevation, fenofi brate use and VTE events risk. It remains to be determined whether or not the use of HCY-lowering treatments, such as folate and vitamin B12 supplementation (47) , might ameliorate any true fenofi brate-related risk of VTE events.
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